威尔药业(603351) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 reached ¥329,832,361.62, representing a year-on-year increase of 33.84%[3] - Net profit attributable to shareholders was ¥34,603,545.42, up 31.52% compared to the same period last year[3] - The basic earnings per share increased by 30.00% to ¥0.26[3] - Operating profit for Q1 2024 was ¥40,841,033.43, a 29.0% increase from ¥31,637,464.96 in Q1 2023[18] - Net profit for Q1 2024 was ¥33,516,432.21, up 30.8% compared to ¥25,635,740.84 in Q1 2023[18] - Total operating revenue for Q1 2024 reached ¥329,832,361.62, a 33.8% increase from ¥246,445,272.15 in Q1 2023[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,288,161,826.46, a slight increase of 0.41% from the previous year[4] - The company's total liabilities decreased to CNY 660,591,429.12 from CNY 686,221,568.07, reflecting a reduction of approximately 3.5%[14] - Current assets increased to CNY 626,214,281.51, up from CNY 599,420,990.91, representing a growth of about 4.4%[12] - The company's equity attributable to shareholders rose to CNY 1,620,399,452.60 from CNY 1,584,423,033.38, reflecting an increase of about 2.3%[14] - Short-term borrowings decreased to CNY 344,456,852.78 from CNY 362,221,219.44, a reduction of approximately 4.8%[14] Cash Flow - Cash flow from operating activities amounted to ¥29,588,625.58, reflecting a significant increase due to higher revenue and improved collections[6] - Cash inflow from operating activities totaled ¥273,321,097.29, compared to ¥195,564,220.36 in the same period last year[21] - The company incurred a net cash outflow of -¥28,831,323.60 from financing activities in Q1 2024, compared to a net inflow of ¥72,635,872.05 in Q1 2023[21] - The net increase in cash and cash equivalents for Q1 2024 was -10,610,391.33, compared to an increase of 28,494,545.92 in the same period last year[22] - The beginning balance of cash and cash equivalents was 157,546,346.64, while the ending balance for Q1 2024 was 146,935,955.31[22] Expenses - The company's sales expenses increased by 51.07%, primarily due to higher sales compensation[6] - The company reported a 41.97% increase in operating costs, attributed to higher sales volume and increased export transportation costs[6] - Research and development expenses increased to ¥15,768,635.95, representing a 21.7% rise from ¥12,944,144.72 in the previous year[17] - Total operating costs for Q1 2024 were ¥290,059,404.32, up 35.0% from ¥214,807,670.05 in Q1 2023[17] - The company reported a decrease in financial expenses to ¥2,390,182.73 from ¥3,843,378.78 in the previous year[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 5,510[8] - The company reported a total of 10 major shareholders, with the largest shareholder holding 18,521,981 shares[9] Other Information - The company has not disclosed any significant new strategies or product developments in the current report[10] - The company is not applying new accounting standards or interpretations for the first time in 2024[22]